Zacks Investment Research Downgrades Aptinyx (NASDAQ:APTX) to Hold

Zacks Investment Research lowered shares of Aptinyx (NASDAQ:APTX) from a strong-buy rating to a hold rating in a research note published on Thursday, Zacks.com reports.

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “

APTX has been the subject of several other reports. JPMorgan Chase & Co. lowered Aptinyx from a neutral rating to an underweight rating in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated a buy rating on shares of Aptinyx in a research report on Tuesday, April 30th. Cowen reiterated a buy rating on shares of Aptinyx in a research report on Monday, June 10th. Svb Leerink initiated coverage on Aptinyx in a research report on Thursday, June 20th. They issued an outperform rating and a $12.00 price objective for the company. Finally, ValuEngine upgraded Aptinyx from a hold rating to a buy rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $12.63.



Shares of Aptinyx stock opened at $3.22 on Thursday. The firm has a market capitalization of $109.75 million, a price-to-earnings ratio of -1.22 and a beta of -0.03. Aptinyx has a fifty-two week low of $2.88 and a fifty-two week high of $32.25. The stock has a 50 day moving average of $3.61 and a 200 day moving average of $4.01.

Aptinyx (NASDAQ:APTX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.16. The company had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative return on equity of 40.01% and a negative net margin of 1,504.24%. Equities research analysts predict that Aptinyx will post -1.95 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Aptinyx by 56.6% during the second quarter. Vanguard Group Inc. now owns 728,689 shares of the company’s stock worth $2,434,000 after buying an additional 263,458 shares during the period. Marshall Wace LLP purchased a new position in shares of Aptinyx during the first quarter worth $1,018,000. Jane Street Group LLC purchased a new position in shares of Aptinyx during the second quarter worth $222,000. Paloma Partners Management Co purchased a new position in shares of Aptinyx during the second quarter worth $207,000. Finally, Spark Investment Management LLC purchased a new position in shares of Aptinyx during the first quarter worth $244,000. Institutional investors own 58.30% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: Green Investing

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.